Manuel Ayala
Impact in
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 10
- Chronic Myeloid Leukemia Treatments 10
- Genetics 9
- Chronic Lymphocytic Leukemia Research 8
- Myeloproliferative Neoplasms: Diagnosis and Treatment 1
- Co-authors
- Jörge E. Cortes (5 shared papers)Sandip Shah (3 shared papers)Michele Baccarani (3 shared papers)M. Brigid Bradley‐Garelik (3 shared papers)Beatriz Moiraghi (3 shared papers)Hagop M. Kantarjian (2 shared papers)Chao Zhu (3 shared papers)Andreas Hochhaus (3 shared papers)
In The Last Decade
Manuel Ayala
9 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 50
- Hematology 1.0k
- Genetics 854
- Rheumatology 548
- Oncology 172
- Pathology and Forensic Medicine 97
Countries citing papers authored by Manuel Ayala
This map shows the geographic impact of Manuel Ayala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Ayala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Ayala more than expected).
Fields of papers citing papers by Manuel Ayala
This network shows the impact of papers produced by Manuel Ayala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Ayala. The network helps show where Manuel Ayala may publish in the future.
Co-authors
The 25 scholars most cited alongside Manuel Ayala, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hit paper breakdown → | 2010 | 1103 |
| 2 | 2016 | 26 | |
| 3 | 2010 | 10 | |
| 4 | 2013 | 7 | |
| 5 | 2015 | 3 | |
| 6 | 2016 | 3 | |
| 7 | 2016 | 1 | |
| 8 | 2012 | 1 | |
| 9 | Dasatinib compared to imatinib in patients with newly diagnosedchronic-phase chronic myelogenous leukemia (CML-CP): resultsfrom the randomized phase 3 dasision tria | 2010 | 1 |
| 10 | 2007 | 0 |
About Manuel Ayala
Manuel Ayala is a scholar working on Hematology, Genetics, Rheumatology, Organic Chemistry and Cardiology and Cardiovascular Medicine, having authored 10 papers that have together received 1.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (8 papers), Eosinophilic Disorders and Syndromes (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (1 paper), Chemotherapy-induced cardiotoxicity and mitigation (1 paper), Acute Lymphoblastic Leukemia research (1 paper) and Synthesis of Tetrazole Derivatives (1 paper). The work is most often cited by research in Hematology (1.0k citations), Genetics (854 citations), Rheumatology (548 citations), Oncology (172 citations) and Pathology and Forensic Medicine (97 citations). Manuel Ayala has collaborated with scholars based in Mexico, Germany and Argentina. Frequent co-authors include Jörge E. Cortes, Sandip Shah, Michele Baccarani, M. Brigid Bradley‐Garelik, Beatriz Moiraghi, Hagop M. Kantarjian, Chao Zhu, Andreas Hochhaus, Françoise Huguet and Eric Bleickardt. Their work appears in journals such as Blood, Journal of Clinical Oncology, The Lancet Haematology, New England Journal of Medicine and Clinical Lymphoma Myeloma & Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.